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Radiofrequency ablation (RFA) is an endoscopic modality used in the treatment of Barrett's
esophagus. RFA may be performed using a balloon-based catheter or using one of the probe
catheters that attaches to the distal end of the endoscope. Here we demonstrate step-by-step
instruction in using radiofrequency ablation in the treatment of Barrett's esophagus and
highlight key concepts in the technique.
& 2014 The Authors. Published by Elsevier GmbH. Open access under CC BY-NC-ND license.Video Related to this Article
Video related to this article can be found online at http://
dx.doi.org/10.1016/j.vjgien.2013.03.001.hed by Elsevier GmbH.
13.03.001
y to the corresponding video.
702 5997;
e.bsd.uchicago.edu
Open access1. Background undBarrett's esophagus (BE) is a risk factor for esophageal
cancer. Endoscopic therapy has become the mainstay of
treatment for high-grade dysplasia and intramucosal
carcinoma in the setting of BE. Radiofrequency ablation
(RFA) has emerged as a widely utilized method of
ablation. RFA applies direct thermal energy to the esophageal
mucosa using electrodes embedded in a circumferential
balloon or a probe catheter. The HALO Flex generator
system is used with a variety of ablation catheters: HALO
360; HALO 90; HALO 90 Ultra; and HALO 60. Any visible or raised lesion in the setting of BE with
dysplasia should be addressed with endoscopic mucosal
resection (EMR) in order to provide an accurate histolo-
gical diagnosis and staging, as well as eradicate the
lesion.er CC BY-NC-ND license.
V.J.A. Konda et al.612 RFA may be used to treat either the remainder of the
Barrett's esophagus after focal EMR in a hybrid approach
of therapy or to ablate ﬂat Barrett's esophagus as the
primary modality.
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 An ablation catheter.
○ Halo 360.1
○ Halo 90.
○ Halo 90 Ultra.
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ing
ide
rks
ft son
ba
wi
he
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 N-acetylcysteine.3. Endoscopic procedure RFA of Barrett's esophagus using the HALO 360 probe
catheter. RFA of Barrett's esophagus using the HALO 90 probe
catheter. Introduction of the other ablation probes available
including HALO 90 Ultra and HALO 60 probe catheters.
4. Discussion
Successful complete eradication of Barrett's esophagus and
associated neoplasia has been demonstrated with an initial
endoscopic mucosal resection for visible abnormalities as
needed, followed by circumferential application, and then
followed by serial focal applications [1].
In a randomized, sham-controlled trial, patients with
high-grade dysplasia (HGD) demonstrated complete eradi-
cation in 81.0% of cases treated with RFA compared to 19.0%
in the sham-control group. Disease progression was lower in
the ablation group (3.6% vs. 16.3%) and fewer cancers were
noted (1.2% vs. 9.3%) [2]. Durability data was also published
demonstrating 98% eradication of dysplasia and 91% eradi-
cation of metaplasia at 3 years [3].
A randomized control trial examined patient with HGD or
early cancer in BE that was less than 5 cm in length. Patients
were randomized to two groups: stepwise radical endo-
scopic resection (SRER) where focal EMR is followed by
serial EMR or EMR/RFA where focal EMR is followed by RFA
[4]. The SRER arm had complete remission at 100% and theal materials for use with Halo 360.
lloon.
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ping cap.EMR/RFA group had complete remission at 96%. The SRER
group had a signiﬁcantly higher rate of stenosis compared to
the EMR/RFA group. This study demonstrated that RFA can
successfully eradicate remaining BE after focal EMR of
visible lesions with a low rate of complications.
The efﬁcacy and safety of RFA has also been demonstrated in
patients with BE without dysplasia. The AIM II trial reported 98%
complete remission of IM after stepwise circumferential therapy
with additional focal ablative therapy of remaining BE with a
2.5 year follow up [5]. Five-year data demonstrates complete
remission of intestinal metaplasia in 92% [6]. Select patients
with non-dysplastic Barrett's esophagus may beneﬁt from RFA;
however, published guidelines have not clariﬁed how best to
stratify these patients.
While the rate of buried glands is reportedly low after
RFA, further work is needed to optimize biopsy protocol and
understand the biological potential of buried metaplasia
[7]. Cases of subsquamous neoplasia after endoscopic
therapy with RFA underscore that surveillance after RFA is
still necessary [8,9].
5. Tips and tricks N-acetylcysteine may be sprayed onto the Barrett's
segment to clear the ablation surface. The Halo 360 Balloon may be used to treat long segment,
circumferential Barrett's esophagus. Prior to treatment,
a sizing balloon is used to select the recommended size
of the Halo 360 balloon. A ﬁrm grip over the balloon catheter and endoscope should
be used to prevent balloon migration during inﬂation. The Halo 90, Halo 90 Ultra, and Halo 60 probe catheters
may be used to treat areas of Barrett's esophagus in a
focal manner. The probe catheter is attached to the
distal end of the scope and is positioned between 10
o'clock and 2 o'clock. The speciﬁc probe catheter may be
selected based on the desired footprint of treatment and
need for maneuverability. When using one of the probe catheters circumferentially
at the gastroesophageal junction, torque the scope to
move the probe clockwise to a position adjacent to the
previously treated area rather than pulling scope back
and advancing scope to reposition. The recommended sequence for treatment with the Halo
360 and Halo 90 Ultra is to ablate the segment with one
application of energy per area, scrape the mucosal
surface and the clean the electrode, and then repeat
ablation to the segment for another application. The recommended sequence for treatment with the Halo
90 and Halo 60 is to ablate the segment with two
applications per area, scrape the mucosal surface and the
clean the electrode, and then repeat ablation to the
segment with an additional applications of energy per area.
6. Scripted voiceoverVoiceover Text
Barrett’s esophagus is a risk factor for esophageal cancer.
Endoscopic therapy has become the mainstay of treatment
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for Barrett’s associated neoplasia. Radiofrequency ablation
(RFA) is one type of endoscopic modality used in practice. RFA
may be used as the primary treatment of a ﬂat segment of
Barrett’s esophagus. Also, following endoscopic mucosal
resection of visible lesions, RFA may also be used to eradicate
the remainder of Barrett’s esophagus.
The HALO generator system delivers radiofrequency energy
to the esophageal mucosa in a uniform manner to a depth
of approximately 800 microns. This procedure uses the
endoscope, the generator and an ablation catheters.
The Halo 360, is an inﬂatable 4 cm balloon with electrodes
that span 3cm.
The Halo 90. a distal attachment, measures 20x13mm.
Compared to the Halo 90, the Halo 90 Ultra has twice the
length and the Halo 60 has 60% of the surface area.
Careful inspection with high deﬁnition of the Barrett’s
segment should be performed.
Document the top of the gastric folds and intestinal
metaplasia.
Narrow band imaging may also identify lesions. Any visible
lesions should be resected.
Spray N-acetylcysteine to clear the surface.
The Halo360 is suited for long segments.
Several pieces of equipment are needed.
This animation demonstrates the sizing. Place a guidewire
into the stomach and withdraw the endoscope.
Position the sizing balloon 12cm above the gastroesophageal
junction.
Obtain measurements in 1cm increments down the entire
esophagus.
As demonstrated, the sizing catheter is attached to the
generator with an intervening ﬁlter.
With the plastic sheath over the balloon, the balloon is
calibrated.
Over the guidewire, the balloon is positioned 12cm above
the gastroesophagealjunction.
Measurements are obtained by inﬂating the balloon with an
inﬂation foot pedal. Advance the balloon by 1 cm and re-
inﬂate and repeat through the esophagus.
A size per measurement is recommended.
Use the smallest recommended size for ablation.
A sudden increase of size may indicate that the balloon has
entered the stomach.
Withdraw catheter and leave the guidewire
This animation shows the HALO360 catheter, over the
guidewire, admisitering the ﬁrst application under
endoscopic guidance.
Then probe and endoscope are withdrawn. A cap is then
used to remove coagulum from the treated area.
With guidewire re-positioned, a second application with the
balloon is performed under endoscopic guidance.
As demonstrated, the balloon catheter is advanced over the
wire.
Pass the endoscope alongside the catheter.
Connect the catheter to generator and ﬁlter.
The electrodes are positioned at the top of the Barrett’s.
Inﬂate the balloon and administer ablation with foot pedals.
Suctioning will help oppose the mucosa and electrodes.
Firmly grip both catheter and endoscope to avoid balloon
migration.
The balloon and endoscope are then advanced
approximately 3 cm. Allow a small overlap between the
electrodes and the treated area.Voiceover Text
Inﬂate the balloon and apply treatment. Repeat as needed.
Disconnect the catheter from generator during insertion or
removal.
Withdraw the deﬂated balloon and endoscope.
Place a soft cap on the endoscope to scrape off the ablated
coagulum.
Replace guidewire and withdraw endoscope.
Clean balloon with water along the grooves.
Reinsert the catheter and pass scope along the catheter.
Perform another treatment. Target any areas missed with
the ﬁrst treatment.
The entire segment receives one application, cleaning, and
one more application with the Halo360.
Use the HALO90 catheter for focal or residual areas, short
segments, or areas in difﬁcult anatomy where the balloon
apposition may be suboptimal.
Prepare the necessary equipment.
Brieﬂy, the HALO 90 probe, attached to the scope tip, is
inserted and .areas are then targeted for ablation. Two
applications are delivered to each area and to other
desired locations. Clean coagulum with the device itself.
Repeat treatment again.
The HALO 90 probe is attached to the scope tip.
The probe should ﬂex and be visible at 12 o’clock.
Intubate the scope carefully and advance to the target area.
Attach the catheter to the generator.
For circumferential treatment, start distally. Place the probe
across the gastro-esophageal junction. Tip probe upward
to ensure good contact.
Apply two applications to tissue with the ablation pedal.
For improved circumferential application, do not pull back
the endoscope. Rather, torque the scope clockwise and
place the probe directly adjacent to the prior ablated
tissue. Administer two ablations to each site and then
repeat until the entire circumference has been ablated.
Treat focal areas as needed.
Disconnect the probe from the generator. Use the probe to
scrape off coagulum.
Withdraw both endoscope and probe.
Clean the probe with water along the grooves.
Treat again with two applications to each site.
The segment receives 2 treatments, cleaning, and 2 more
treatments with the HALO90.
The longer HALO90 Ultra probe and can be used to treat
larger areas or where the balloon may have suboptimal
apposition, as with large hiatal hernias. The Halo90 Ultra
protocol requires one treatment, cleaning, and one more
treatment.
The smaller HALO60 probe may be used for focal areas,
settings with strictures, or to get between folds at gastro-
esophageal junction. The Halo60 is used in an identical
protocol as the HALO 90.
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